BioLife Solutions (BioLife Solutions) Capex-to-Revenue : 0.03 (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is BioLife Solutions Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

BioLife Solutions's Capital Expenditure for the three months ended in Dec. 2023 was $-0.98 Mil. Its Revenue for the three months ended in Dec. 2023 was $32.73 Mil.

Hence, BioLife Solutions's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.03.

BioLife Solutions Capex-to-Revenue Historical Data

The historical data trend for BioLife Solutions's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLife Solutions Capex-to-Revenue Chart

BioLife Solutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Revenue

Get a 7-Day Free Trial

0.03

0.10

0.07

0.06

0.05

BioLife Solutions Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Capex-to-Revenue	Get a 7-Day Free Trial															0.10	0.09	0.02	0.05	0.03

Competitive Comparison of BioLife Solutions's Capex-to-Revenue

For the Medical Instruments & Supplies subindustry, BioLife Solutions's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLife Solutions's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where BioLife Solutions's Capex-to-Revenue falls into.

BioLife Solutions Capex-to-Revenue Calculation

BioLife Solutions's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-6.381)	/	143.271
	=	0.04

BioLife Solutions's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.981)	/	32.733
	=	0.03

BioLife Solutions (NAS:BLFS) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

BioLife Solutions Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of BioLife Solutions's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLife Solutions (BioLife Solutions) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (NAS:BLFS) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

BJX1:Germany

Address

3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021

Website

https://www.biolifesolutions.com

BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.

Executives

Geraint Phillips	officer: SVP, Global Operations	3303 MONTE VILLA, #310, BOTHELL WA 98021
Sarah Aebersold	officer: VP, Global Human Resources	BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Troy Wichterman	officer: Chief Financial Officer	3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Greef Roderick De	director
Aby J. Mathew	officer: Chief Tech. Officer & Sr. VP	3303 MONTE VILLA PARKWAY, #310, BOTHELL WA 98021
Todd Berard	officer: Vice President, Marketing	3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Karen A. Foster	officer: Vice President of Operations	C/O BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Michael Rice	director, officer: President & CEO	C/O BIOLIFE SOLUTIONS, INC., 171 FRONT STREET, OWEGO NY 13827
Casdin Partners Master Fund, L.p.	10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Garrie Richardson	officer: Chief Revenue Officer	3303 MONTE VILA PARKWAY, BOTHELL WA 98021
Marcus Schulz	officer: Vice President, Global Sales	3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Joseph C Schick	director	16719 NE 139TH PLACE, WOODINVILLE WA 98072
Amy Duross	director	8410 GOLDEN BEAR PLACE, WHISTLER A1 V8E 1J7
Timothy L. Moore	director	C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Joydeep Goswami	director	SUMITOMO FUDOSAN MITA TWIN BLDG, EAST WING 4-2-8 SHIBAURA MINATO-KU, TOKYO M0 1080023